Evidence map›Paper›PMID 27640125›Full record

ArticleMicrobiome2016

Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study.

Janice Crespo-Salgado, V Matti Vehaskari, Tyrus Stewart, Michael Ferris, Qiang Zhang, Guangdi Wang, Eugene E Blanchard, Christopher M Taylor, Mahmoud Kallash, Larry A Greenbaum and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiome, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 5 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 5 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Pediatric and adult point of view on the gut-kidney axis in CKD.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Janice Crespo-SalgadoChildren's Hospital, New Orleans, LA, USA.
V Matti VehaskariChildren's Hospital, New Orleans, LA, USA.
Tyrus StewartChildren's Hospital, New Orleans, LA, USA.
Michael FerrisChildren's Hospital, New Orleans, LA, USA.
Qiang ZhangXavier University of Louisiana, New Orleans, LA, USA.
Guangdi WangXavier University of Louisiana, New Orleans, LA, USA.
Eugene E BlanchardLouisiana State University Health Sciences Center, New Orleans, LA, USA.
Christopher M TaylorLouisiana State University Health Sciences Center, New Orleans, LA, USA.
Mahmoud KallashUniversity at Buffalo, Buffalo, NY, USA.
Larry A GreenbaumEmory University and Children's Healthcare of Atlanta, Atlanta, GA, USA.
Diego H AvilesChildren's Hospital, New Orleans, LA, USA. davile@lsuhsc.edu.
Louisiana State University Health Sciences Center New Orleans · USChildren's Hospital of New Orleans · USXavier University of Louisiana · USChildren's Healthcare of Atlanta · USUniversity at Buffalo, State University of New York · US

Funding

Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7M
NIMHD NIH HHS G12 MD007595
6 · The paper itself

Abstract

backgroundEnd-stage renal disease (ESRD) is associated with uremia and increased systemic inflammation. Alteration of the intestinal microbiota may facilitate translocation of endotoxins into the systemic circulation leading to inflammation. We hypothesized that children with ESRD have an altered intestinal microbiota and increased serum levels of bacterially derived uremic toxins.

methodsFour groups of subjects were recruited: peritoneal dialysis (PD), hemodialysis (HD), post-kidney transplant and healthy controls. Stool bacterial composition was assessed by pyrosequencing analysis of 16S rRNA genes. Serum levels of C-reactive protein (CRP), D-lactate, p-cresyl sulfate and indoxyl sulfate were measured.

resultsCompared to controls, the relative abundance of Firmicutes (P = 0.0228) and Actinobacteria (P = 0.0040) was decreased in PD patients. The relative abundance of Bacteroidetes was increased in HD patients (P = 0.0462). Compared to HD patients the relative abundance of Proteobacteria (P = 0.0233) was increased in PD patients. At the family level, Enterobacteriaceae was significantly increased in PD patients (P = 0.0020) compared to controls; whereas, Bifidobacteria showed a significant decrease in PD and transplant patients (P = 0.0020) compared to control. Alpha diversity was decreased in PD patients and kidney transplant using both phylogenetic and non-phylogenetic diversity measures (P = 0.0031 and 0.0003, respectively), while beta diversity showed significant separation (R statistic = 0.2656, P = 0.010) between PD patients and controls. ESRD patients had increased serum levels of p-cresyl sulfate and indoxyl sulfate (P < 0.0001 and P < 0.0001, respectively). The data suggests that no significant correlation exists between the alpha diversity of the intestinal microbiota and CRP, D-lactate, or uremic toxins. Oral iron supplementation results in expansion of the phylum Proteobacteria.

conclusionsChildren with ESRD have altered intestinal microbiota and increased bacterially derived serum uremic toxins.

Indexed as

ActinobacteriaAdolescentBacillotaBacterial LoadBacteroidetesChildChild, PreschoolC-Reactive ProteinCresolsFecesFemaleGastrointestinal MicrobiomeHumansIndicanIntestinesKidney Failure, Chronic4-cresol sulfateC-Reactive ProteinCresolsIndicanLactic AcidRNA, Ribosomal, 16SSulfuric Acid EstersChildrenEnd-stage renal diseaseInflammationIntestinal microbiotaPyrosequencingUremic toxins

Identifiers

PMID27640125
PMCPMC5027112
OpenAlexW2520431487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.